473913-08-5

Upstream product

• 2393-23-9 4-methoxy-benzylamine 
• 220290-97-1 (3aS,4S,6R,6aR)-4-Allyl-6-methoxy-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid methyl ester 
• 473913-06-3 (3aS,4S,6R,6aR)-4-(2,3-Dibromo-propyl)-6-methoxy-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid methyl ester 
• 473913-02-9 (3aS,4S,6aS)-5-Bromo-4-(2,3-dibromo-propyl)-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[1,3]dioxol-4-ol 
• 473913-00-7 (3aS,4S,6aS)-4-Allyl-5-bromo-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[1,3]dioxol-4-ol 
• 158531-14-7 2-bromo-4,5-O-isopropylidene-2-cyclopenten-1-one 

Downstream Products

• 473913-10-9 C₁₁H₁₇NO₅ 
• 473913-11-0 C₁₉H₂₃NO₇ 

Relevant academic research and scientific papers

Structural determinants of A3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary

Mutagenesis of the human A3 adenosine receptor (AR) suggested that certain amino acid residues contributed differently to ligand binding and activation processes. Here we demonstrated that various adenosine modifications, including adenine subs